Status:
COMPLETED
Automated Prediction and Prevention of Contrast Induced Nephropathy After Cardiac Catheterization
Lead Sponsor:
University of Chicago
Collaborating Sponsors:
Philips Healthcare
Conditions:
Contrast-induced Nephropathy
Eligibility:
All Genders
21+ years
Brief Summary
Contrast agent is typically used during routine cardiac intervention in order to enhance the imaging necessary to perform the procedure. Using this contrast agent could lead to kidney injury, called c...
Detailed Description
This is a case-control series comparing a strategy using a computer-based contrast induced nephropathy (CBCIN) risk tool in patients undergoing PCI versus usual care. Only inpatients will be included ...
Eligibility Criteria
Inclusion
- Inpatients age ≥ 21 years seen at the University of Chicago Medical Center with a clinical indication for cardiac catheterization with high likelihood of PCI, or those undergoing planned PCI will be screened for enrollment into our study. Following PCI, these patients must have at least two consecutive daily creatinine measurements starting the day after the PCI, but clinically-indicated according to the inpatient treating physician.
Exclusion
- Patients being discharged the day after the PCI.
- Patients who are screened but do not receive PCI.
- Patients who do not have at least two consecutive daily creatinine measurements starting the day after the PCI.
- Patients undergoing emergency primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
- Patients in cardiogenic shock.
- Patients with end-stage renal disease or who are on renal replacement therapy.
- Patients requiring planned mechanical circulatory support for the PCI.
- Pregnant women (standard PCI screening)
- Vulnerable populations such as children, college students, prisoners, non-English speakers, and those with diminished decision-making capacity
- Inability or refusal to consent for the study.
Key Trial Info
Start Date :
March 7 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 17 2023
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT03305874
Start Date
March 7 2018
End Date
July 17 2023
Last Update
August 24 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Chicago
Chicago, Illinois, United States, 60637